Education
About Us
Working with TipRanks
Follow Us
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H (HK:2185)
:2185
RESEARCH TOOLSreports
2185 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$1.26 - HK$5.00
Previous CloseN/A
Volume27.00K
Average Volume (3M)1.08M
Market Cap
HK$1.96B
Enterprise ValueHK$612.53M
Total Cash (Recent Filing)HK$202.39M
Total Debt (Recent Filing)¥8.28M
Price to Earnings (P/E)―
Beta1.54
Next Earnings
Aug 01, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding236,223,330
10 Day Avg. Volume1,292,778
30 Day Avg. Volume1,075,562
Financial Highlights & Ratios
PEG Ratio-0.80
Price to Book (P/B)1.26
Price to Sales (P/S)0.00
P/FCF Ratio-8.33K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H News
PremiumCompany Announcements
Shanghai Bio-heart Approves Key Resolutions at 2024 AGM
PremiumCompany Announcements
Shanghai Bio-heart Announces Waiver for Share Buy-back Proposal
PremiumCompany Announcements
Shanghai Bio-heart Launches Clinical Trial for Sirolimus DCB in Japan
PremiumCompany Announcements
Shanghai Bio-Heart Reports Reduced Losses and Key Milestones in 2024
PremiumCompany Announcements
Shanghai Bio-Heart Announces Board Composition and Roles
PremiumCompany Announcements
Shanghai Bio-Heart Forms Nomination Committee to Enhance Board Governance2185 FAQ
What was Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s price range in the past 12 months?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H lowest stock price was HK$1.26 and its highest was HK$5.00 in the past 12 months.
What is Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s market cap?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s market cap is HK$1.96B.
When is Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s upcoming earnings report date?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s upcoming earnings report date is Aug 01, 2025 which is in 13 days.
How were Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s earnings last quarter?
Currently, no data Available
Is Shanghai Bio-Heart Biological Technology Co., Ltd. Class H overvalued?
According to Wall Street analysts Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s price is currently Overvalued.
Does Shanghai Bio-Heart Biological Technology Co., Ltd. Class H pay dividends?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H does not currently pay dividends.
What is Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s EPS estimate?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shanghai Bio-Heart Biological Technology Co., Ltd. Class H have?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H has 236,223,330 shares outstanding.
What happened to Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Shanghai Bio-Heart Biological Technology Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2185
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
129.47%
12-Months-Change
Fundamentals
Return on Equity
-12.49%
Trailing 12-Months
Asset Growth
-13.28%
Trailing 12-Months
Company Description
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H (2185) is a biotechnology company that specializes in the research, development, and commercialization of innovative medical devices and technologies. Primarily operating in the healthcare sector, the company focuses on products that address cardiovascular diseases. Its core offerings include advanced therapeutic solutions and diagnostic tools designed to improve patient outcomes and enhance the efficiency of healthcare delivery.
Technical Analysis
CanSino Biologics, Inc. Class H
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Akeso, Inc.
―
Shanghai Fosun Pharmaceutical (Group) Co
―
Wuxi Biologics (Cayman)
―